Table 5.
Visual analog scale pain scale scores following viscosupplementation.
| Study/Interval |
Baseline |
Follow-Up |
p-value | ||
|---|---|---|---|---|---|
| 1-month | Mean | SD | Mean | SD | |
| Clementi et al. 201819 | |||||
| UHMW | 6.4 | 1.7 | 5.1 | 1.6 | – |
| MMW | 6.3 | 2.1 | 4.9 | 1.8 | – |
| Di Sante et al. 201636 | 6.32 | 1.7 | 5.27 | 1.6 | <0.01 |
| Battaglia et al. 201338 | 5.97 | – | 3.58 | – | |
| Eyigor et al. 201024 | 7.52 | – | 2.81 | – | <0.001 |
| Dıraçoğlu et al. 200939 | 6.88 | 0.99 | 3.12 | 1.22 | <0.001 |
| Tikiz et al. 200531 | |||||
| Na-Hyaluronate | 7.2 | 1.5 | 4.1 | 2.6 | <0.001 |
| Hylan G-F 20 | 6.7 | 1.7 | 4.4 | 2.3 | <0.001 |
| Migliore et al. 200532 | 7.81 | – | 5.87 | – | <0.05 |
| Caglar-Yagci et al. 200533 | 77.35 | 13.74 | 48.92 | 21.62 | <0.001 |
| Brocq et al. 200234 | 55.4 | 14.9 | 30.7 | 22.2 | – |
| 6-weeks | |||||
| Van Den Bekerom et al. 200841 | |||||
| Adant® | 51 | 23 | 39 | 27 | <0.0001 |
| Synocrom® | 43 | 22 | 29 | 23 | <0.02 |
| Synvisc® | 47 | 26 | 30 | 29 | >0.05 |
| Van Den Bekerom et al. 200643 | 66.3 | – | 49.3 | – | |
| 2-months | |||||
| Miglore et al. 200529 | 6.85 | 2.08 | 4.04 | 2.56 | <0.001 |
| Pourbagher et al. 200545 | 8.3 | 0.56 | 4.75 | 0.64 | – |
| Brocq et al. 200234 | 55.4 | 14.9 | 30.5 | 24.8 | – |
| 10-weeks | |||||
| Mauro et al. 201720 | 6.18 | 2.537 | 1.31 | 1.478 | <0.05 |
| 3-months | |||||
| Clementi et al. 201819 | |||||
| UHMW | 6.4 | 1.7 | 4.7 | 1.3 | – |
| MMW | 6.3 | 2.1 | 4.5 | 1.5 | – |
| Abate et al. 201722 | |||||
| HI LOW Hybrid | 4.5 | 1 | 3.3 | 0.8 | <0.001 |
| HMW | 4.4 | 1.5 | 3.5 | 1.3 | <0.001 |
| Battaglia et al. 201338 | 5.97 | – | 3.8 | – | – |
| Eyigor et al. 201024 | 7.52 | – | 2.9 | – | <0.001 |
| Migliore et al. 200925 | 6 | – | 3.72 | – | <0.0005 |
| Migliore et al. 200927 | 6.4 | 1.94 | 4.3 | 2.58 | – |
| Migliore et al. 200530 | 6.5 | 2.1 | 4.4 | 2.1 | <0.05 |
| Tikiz et al. 200531 | |||||
| Na-Hyaluronate | 7.2 | 1.5 | 4.6 | 2.5 | <0.001 |
| Hylan G-F 20 | 6.7 | 1.7 | 4.7 | 2.7 | <0.001 |
| Migliore et al. 200532 | 7.81 | – | 5.25 | – | 0.004 |
| Caglar-Yagci et al. 200533 | 77.35 | 13.74 | 28.57 | 19.87 | <0.001 |
| Conrozier et al. 200346 | 69.3 | 11.9 | 39.5 | 29.5 | <0.0001 |
| Brocq et al. 200234 | 55.4 | 14.9 | 30.4 | 22.2 | – |
| 4-months | |||||
| Di Sante et al. 201636 | 6.32 | 1.7 | 3.63 | 2.1 | – |
| Pourbagher et al. 200545 | 8.3 | 0.56 | 20.9 | 6.37 | – |
| 159 days (range: 60–180) | |||||
| Conrozier et al. 200926 | 51.9 | 20.8 | 31.1 | 4.1 | 0.0001 |
| 6-months | |||||
| Clementi et al. 201819 | |||||
| UHMW | 6.4 | 1.7 | 5 | 1.5 | – |
| MMW | 6.3 | 2.1 | 4.7 | 1.3 | – |
| Doria et al. 201735 | 7.8 | 1.9 | 6.3 | 2.9 | 0.0007 |
| Abate et al. 201722 | |||||
| HI LOW Hybrid | 4.5 | 1 | 2.5 | 0.8 | <0.001 |
| HMW | 4.4 | 1.5 | 3.2 | 1.2 | <0.001 |
| Battaglia et al. 201338 | 5.97 | – | 4.04 | – | – |
| Eyigor et al. 201024 | 7.52 | – | 4.52 | – | – |
| Migliore et al. 200925 | 6 | – | 4.17 | – | <0.0005 |
| Migliore et al. 200927 | 6.4 | 1.94 | 4.5 | 1.96 | – |
| Miglore et al. 200529 | 6.85 | 2.08 | 4.26 | 3.04 | <0.001 |
| Migliore et al. 200530 | 6.5 | 2.1 | 5 | 2.3 | <0.05 |
| Pourbagher et al. 200545 | 8.3 | 0.56 | 4.4 | 0.7 | – |
| Tikiz et al. 200531 | |||||
| Na-Hyaluronate | 7.2 | 1.5 | 4.6 | 2.5 | <0.001 |
| Hylan G-F 20 | 6.7 | 1.7 | 3.4 | 3 | <0.001 |
| Brocq et al. 200234 | 55.4 | 14.9 | 24.7 | 17.1 | – |
| 9-months | |||||
| Migliore et al. 200925 | 6 | – | 3.88 | – | <0.0005 |
| Migliore et al. 200530 | 6.5 | 2.1 | 4.3 | 3.2 | <0.05 |
| 12-months | |||||
| Clementi et al. 201819 | |||||
| UHMW | 6.4 | 1.7 | 4.8 | 1.6 | – |
| MMW | 6.3 | 2.1 | 4.9 | 1.6 | – |
| Doria et al. 201735 | 7.8 | 1.9 | 6.3 | 2.9 | 0.00654 |
| Battaglia et al. 201338 | 5.97 | – | 4.59 | – | – |
| Migliore et al. 200925 | 6 | – | 3.63 | – | <0.0005 |
| Migliore et al. 200530 | 6.5 | 2.1 | 3.5 | 3 | <0.05 |
| Vad et al. 200347 | 8.7 | – | 2.3 | – | – |
UHMW: Ultra High Molecular Weight; HMW: High Molecular Weight; MMW: Medium Molecular Weight; LMW: Low Molecular Weight.